First patient Archives

First patient

Anaveon doses first patient in a Phase I/II study to evaluate the safety, dosing and clinical activity of ANV419 in patients with solid tumors

by admin | Jun 24, 2021 | Press Releases

ANV419 is a powerful and selective interleukin-2 (IL-2) agonist targeting cancer Basel, 24 June, 2021 – Anaveon, a clinical stage, immuno-oncology company, today announced that it has successfully dosed the first patient in a Phase I/II open label study of ANV419, a...

Anaveon doses first patient in a Phase I/II study to evaluate the safety, dosing and clinical activity of ANV419 in patients with solid tumors

Search here

Categories

Recent Posts

Archives

Anaveon doses first patient in a Phase I/II study to evaluate the safety, dosing and clinical activity of ANV419 in patients with solid tumors

Search here

Categories

Recent Posts

We are social

Popular Tags

Archives